Subject(s)
Eosinophilia , Fasciitis , Humans , Retrospective Studies , Prognosis , Fasciitis/diagnosis , EdemaSubject(s)
COVID-19 , Chilblains , Interferon Type I , Humans , Chilblains/diagnosis , Chilblains/etiology , Chilblains/epidemiology , SARS-CoV-2 , PandemicsABSTRACT
is missing (Short communication).
Subject(s)
Coronavirus Infections/epidemiology , Dermatitis/therapy , Dermatology/organization & administration , Infection Control/organization & administration , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Adult , Aged , COVID-19 , Chronic Disease , Cohort Studies , Coronavirus Infections/prevention & control , Dermatitis/diagnosis , Dermatitis/epidemiology , Dermatologists , Female , Humans , Incidence , Male , Middle Aged , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Retrospective Studies , Risk Assessment , Surveys and Questionnaires , Telemedicine/statistics & numerical dataSubject(s)
Anti-Allergic Agents/therapeutic use , Biological Products/therapeutic use , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Omalizumab/therapeutic use , Psoriasis/drug therapy , Spondylitis, Ankylosing/drug therapy , Urticaria/drug therapy , Adult , Anti-Allergic Agents/adverse effects , Biological Products/adverse effects , Chronic Disease , Colitis, Ulcerative/diagnosis , Colitis, Ulcerative/immunology , Crohn Disease/diagnosis , Crohn Disease/immunology , Female , Humans , Immunoglobulin E/immunology , Male , Middle Aged , Omalizumab/adverse effects , Psoriasis/diagnosis , Psoriasis/immunology , Retrospective Studies , Spondylitis, Ankylosing/diagnosis , Spondylitis, Ankylosing/immunology , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , Urticaria/diagnosis , Urticaria/immunology , Young AdultSubject(s)
Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Autoimmune Diseases/chemically induced , Clostridioides difficile , Clostridium Infections/complications , Colitis/chemically induced , Aged , Autoimmune Diseases/complications , Colitis/complications , Diarrhea/chemically induced , Female , Humans , IpilimumabABSTRACT
BACKGROUND: Wide-excision surgery is required in Darier-Ferrand dermatofibrosarcoma protuberans, but there is no consensus regarding the lateral margins. MATERIALS AND METHODS: We performed a systematic review based on a MEDLINE search of articles, published from 1994 to 2009 to determine the optimal procedure to avoid recurrences and treatment morbidity. RESULTS: The analyzed articles included five meta-analyses of retrospective studies; three prospective, nonrandomized studies; and 35 retrospective studies. DISCUSSION: Positive deep margins may lead to a recurrence independent of lateral margin status. Despite an absence of formal evidence, wide excision with 3-cm margins appears to result in significantly less risk of a recurrence than surgery using <3-cm margins. Negative histologic margins appear to be the best criterion to decrease recurrence. Despite a lack of strong data, there was a marked tendency of Mohs micrographic surgery (MMS) to produce better results than conventional surgery. If MMS is unavailable, surgery using 3-cm lateral margins and a disease-free anatomic zone deep into the lesion is proposed. Slow Mohs could be a safe alternative to MMS when the latter technique is not available. Patients should be followed for a minimum of 10 years and preferably indefinitely.
